The mean decreases in HbA1c at endpoint ( week 12 ) were significantly greater for all three rGLP-1 dose groups when each was compared with the placebo group , with the greatest decrease occurring in the 5.0 pkm dose group ( -1.3 % , s.d. 0.18 , p < 0.001 ) .